Jon CohenScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Success in the push to find a COVID-19 vaccine at record-breaking speed could hand the world a new problem.
The first vaccine to cross the finish line might be only marginally effective, yet it could become the enemy of the good--or even the great—candidates in the wings by disrupting ongoing studies.In all likelihood, the U.S.
Food and Drug Administration (FDA) or other regulators will issue the first COVID-19 vaccine approval or emergency use authorization (EUA) for one vaccine while many other candidates have clinical trials still underway or in the planning.